Scientific Updates to Improve Outcomes in Patients with Pulmonary Arterial Hypertension

Scientific Updates to Improve Outcomes in Patients with Pulmonary Arterial Hypertension

Program Overview

This CME activity will discuss recent advances in the treatment and management of patients with pulmonary arterial hypertension (PAH). The expert faculty will provide learners with a scientific update regarding current evidence-based guidelines and appropriate diagnostic strategies. Recent clinical trial data of new and emerging therapeutic options for the treatment of PAH will be reviewed. The faculty will ...
View Course
Scientific Update on Pulmonary Arterial Hypertension

Scientific Update on Pulmonary Arterial Hypertension

Program Overview

In this module of a Four-Part Expert Interview Series, Inderjit Singh, MBChB, BMedSci, MRCP, along with Aaron B. Waxman, MD, PhD, course chair, will provide a scientific update of pulmonary arterial hypertension (PAH), including the evolution of therapeutic options. The clinical relevance of various precision PAH therapeutics will be debated, among other topics. The role of exercise hemodynamics ...
View Course
Applying Evidence-based Strategies to Patient-Centered Care in PAH

Applying Evidence-based Strategies to Patient-Centered Care in PAH

Program Overview

In this module of a Four-Part Expert Interview Series, Jeffrey Voner, MSHS, MPH, PA-C, DFAAPA, along with Aaron B. Waxman, MD, PhD, course chair, will outline recent treatment data for pulmonary arterial hypertension (PAH) as it relates to interprofessional patient care. Best practices for managing heart failure will be reviewed along with potential treatment directions after a confirmed ...
View Course
Understanding Treatment Options for PAH

Understanding Treatment Options for PAH

Program Overview

In this module of a Four-Part Expert Interview Series, R. James White, MD, along with Aaron B. Waxman, MD, PhD, course chair, will review advancements in the treatment and management of pulmonary arterial hypertension (PAH). The pipeline of available therapies will be relayed, along with strategies for selecting optimal single/combination therapies for PAH patients. The clinical relevance of ...
View Course
Achieving an Earlier Diagnosis in Pulmonary Arterial Hypertension

Achieving an Earlier Diagnosis in Pulmonary Arterial Hypertension

Program Overview

In this module of a Four-Part Expert Interview Series, Evelyn Horn, MD, along with Aaron B. Waxman, MD, PhD, course chair, will discuss best practices for achieving an earlier diagnosis in pulmonary arterial hypertension (PAH). Data supporting early intervention will be analyzed along with risk factors for PAH and screening recommendations derived from current guidelines. The faculty will ...
View Course

Understanding Lipoprotein(a)- Novel Therapeutics to Reduce Lp(a) Levels and Improve Cardiovascular Outcomes

Understanding Lipoprotein(a)- Novel Therapeutics to Reduce Lp(a) Levels and Improve Cardiovascular Outcomes

Program Overview

This CME/CNE program will highlight content presented at the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany. The three expert faculty, led by Dr. Patrick M. Moriarty, will assess the role of lipoprotein(a)- novel therapeutics in reducing Lp(a) levels and improving cardiovascular outcomes. A state of the science of lipoprotein(a), including the mechanism of action, subtypes ...
View Course
Identifying Financial and/or Treatment Access Barriers: Patient Perspectives

Identifying Financial and/or Treatment Access Barriers: Patient Perspectives

Program Overview

In this module of a Four-Part Expert Interview Series, Dr. James A. Underberg, along with Dr Christopher P. Cannon, course chair, will identify barriers to caring for dyslipidemia patients. There barriers will include financial and other patient-related obstacles. This discussion will incorporate strategies to improve access to PCSK9 inhibitors, in turn leading to improved patient outcomes.

Target Audience 

...
View Course
Clinical Trial Analysis of PCSK9 Inhibitors: The Impact of Real-World Cardiovascular Outcomes

Clinical Trial Analysis of PCSK9 Inhibitors: The Impact of Real-World Cardiovascular Outcomes

Program Overview

In this module of a Four-Part Expert Interview Series, Dr. Michael J. Blaha, along with Dr Christopher P. Cannon, course chair, will explore the role of PCSK9 inhibitors in the treatment of dyslipidemia patients and the impact of real-world cardiovascular outcomes. This discussion will aid physicians in providing optimal care in clinical practice.

Target Audience

Cardiologists, internists, and ...
View Course
The Role of PCSK9 Inhibitors in Reducing CV Risk: Patient Selection Criteria and Treatment Initiation Tactics

The Role of PCSK9 Inhibitors in Reducing CV Risk: Patient Selection Criteria and Treatment Initiation Tactics

Program Overview

In this module of a Four-Part Expert Interview Series, Dr. Robert P. Giugliano, along with Dr Christopher P. Cannon, course chair, will examine the role of PCSK9 inhibitors in reducing CV risk. Dr. Guigliano will review optimal patient selection criteria and how it can be applied in daily practice. This module will allow learners to understand the relationship ...
View Course
Further Insights in Lowering LDL Cholesterol: Managing Atherosclerotic Disease in High-Risk Patients

Further Insights in Lowering LDL Cholesterol: Managing Atherosclerotic Disease in High-Risk Patients

Program Overview

In this module of a Four-Part Expert Interview Series, Dr. Marc P. Bonaca, along with Dr. Christopher P. Cannon, course chair, will discuss options for lowering LDL cholesterol in dyslipidemia patients. This will include recent outcomes from clinical trials and the diagnostic criteria of peripheral artery disease. Enabling physicians to recognize physical indicators of PAD will maximize treatment ...
View Course
Loading...